Intensive therapy with high-dose melphalan (MEL) 280 mg/m2 plus amifostine cytoprotection and ASCT as part of initial therapy in patients with multiple myeloma.

被引：0
|
作者：
Reece, DE
Vesole, D
Flomenberg, N
Badros, A
Filicko, J
Herzig, R
Howard, DS
Johnson, V
Meisenberg, B
Rapoport, A
Xun, CQ
Phillips, GL
机构：
[1] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Thomas Jefferson Univ, Coll Med, Philadelphia, PA 19107 USA
[4] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Univ Kentucky, Lexington, KY 40506 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1672
引用
收藏
页码：432A / 432A
页数：1
相关论文
共 50 条
  • [41] Routine care of patients with Multiple Myeloma (MM) 01/2019-12/2020 not suitable for high-dose melphalan therapy followed by autologous stem cell transplantation (ASCT)
    Weide, R.
    Mohm, J.
    Klausmann, M.
    Linde, H.
    Rothe, A.
    Steinmetz, T.
    Hensel, M.
    Ehscheidt, P.
    Reiser, M.
    Doerfel, S.
    Mueller, L.
    Schmidt, B.
    Maasberg, M.
    Burkhard, O.
    Feiten, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 181 - 182
  • [42] Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients
    Boccadoro, Mario
    Cavallo, Federica
    Gay, Francesca Maria
    Di Raimondo, Francesco
    Nagler, Arnon
    Montefusco, Vittorio
    Patriarca, Francesca
    Tacchetti, Paola
    Guglielmelli, Tommasina
    Musto, Pellegrino
    Baldini, Luca
    Crippa, Claudia
    Ruggeri, Marina
    Gentilini, Fabiana
    Cavalli, Maide
    Ben Yehuda, Dina
    Caravita, Tommaso
    Ciccone, Giovannino
    Hardan, Izhar
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Quality of life as an important outcome of high-dose therapy plus autologous stem cell transplantation (HDCT plus ASCT) in multiple sclerosis patients
    Shevchenko, Y
    Novik, A
    Ionova, T
    Lesukov, I
    Kulagin, A
    Malysheva, O
    Melnichenko, V
    Bisaga, G
    Chelombit, L
    Kishtovich, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S213 - S213
  • [44] INTERMEDIATE-DOSE (25 MG/M2) INTRAVENOUS MELPHALAN FOR PATIENTS WITH MULTIPLE-MYELOMA IN RELAPSE OR REFRACTORY TO STANDARD TREATMENT
    PETRUCCI, MT
    AVVISATI, G
    TRIBALTO, M
    CANTONETTI, M
    GIOVANGROSSI, P
    MANDELLI, F
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1989, 42 (03) : 233 - 237
  • [45] Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy
    Facon, T
    Mary, JY
    Pégourie, B
    Attal, M
    Renaud, M
    Sadoun, A
    Voillat, L
    Dorvaux, W
    Hulin, C
    Lepeu, G
    Harousseau, JL
    Eschard, JP
    Ferrant, A
    Blanc, M
    Maloisel, F
    Orfeuvre, H
    Rossi, JF
    Azaïs, I
    Monconduit, M
    Collet, P
    Anglaret, B
    Yakoub-Agha, I
    Wetterwald, M
    Eghbali, H
    Vekemans, MC
    Maisonneuve, H
    Troncy, J
    Grosbois, B
    Doyen, C
    Thyss, A
    Jaubert, J
    Casassus, P
    Thielemans, B
    Bataille, R
    BLOOD, 2006, 107 (04) : 1292 - 1298
  • [46] PHARMACOKINETICS PARAMETERS AND TOXICITY OF HIGH-DOSE 140 MG/M2 MELPHALAN - FEASIBILITY IN PATIENTS WITH SEVERE RENAL-FAILURE
    MOREAU, P
    KERGUERIS, MF
    MILPIED, N
    LEGROS, L
    LAROUSSE, C
    HAROUSSEAU, JL
    BLOOD, 1994, 84 (10) : A657 - A657
  • [47] Total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan (Mel) and PBPC as part of tandem autologous transplant (TAT) for patients with multiple myeloma.
    Somlo, George
    Liu, An
    Schultheiss, Timothy E.
    Frankel, Paul Henry
    Spielberger, Ricardo Tomas
    Popplewell, Leslie
    Zhou, Kenny
    Hawkins, Donna
    Krishnan, Amrita Y.
    Sahebi, Firoozeh
    Parker, Pablo Miguel
    Forman, Stephen J.
    Wong, Jeffrey Y. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Tolerability of high-dose melphalan 200 mg/m2 in patients with myeloma and leukaemia over the age of 65 years:: A single-centre study of 42 patients.
    Powles, R
    Sirohi, B
    Singhal, S
    Kulkarni, S
    Patel, G
    Sankpal, S
    Brennan, J
    Stephens, M
    Treleaven, J
    Mehta, J
    BLOOD, 2002, 100 (11) : 480B - 480B
  • [49] Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
    Jose Lahuerta, Juan
    Victoria Mateos, Maria
    Martinez-Lopez, Joaquin
    Grande, Carlos
    de la Rubia, Javier
    Rosinol, Laura
    Sureda, Anna
    Garcia-Larana, Jose
    Diaz-Mediavilla, Joaquin
    Hernandez-Garcia, Miguel T.
    Carrera, Dolores
    Besalduch, Joan
    de Arriba, Felipe
    Oriol, Albert
    Escoda, Lourdes
    Garcia-Frade, Javier
    Rivas-Gonzalez, Concepcion
    Alegre, Adrian
    Blade, Joan
    San Miguel, Jesus F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1913 - 1920
  • [50] Phase I dose-escalation trial of high-dose melphalan (M) with palifermin (P) for cytoprotection followed by autologous stem cell transplantation (ASCT) for myeloma (MM) patients with normal renal function (NRF)
    Abidi, M. H.
    Tageja, N.
    Al-Kadhimi, Z. S.
    Abrams, J.
    Cronin, S.
    Ventimiglia, M.
    Ayash, L. J.
    Lum, L. G.
    Ratanatharathorn, V.
    Uberti, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345